The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeting G1-S phase cell-cycle alterations with CDK4/6 inhibitor-based genomically matched personalized therapy approach.
 
Jacob J. Adashek
No Relationships to Disclose
 
Shumei Kato
Honoraria - Roche
Consulting or Advisory Role - Foundation Medicine; Foundation Medicine
 
Ryosuke Okamura
No Relationships to Disclose
 
Noor Khalid
No Relationships to Disclose
 
Suzanna Lee
No Relationships to Disclose
 
Van Thomas Nguyen
No Relationships to Disclose
 
Jason K. Sicklick
Consulting or Advisory Role - Deciphera; Grand Rounds; Loxo
Speakers' Bureau - Roche
Research Funding - Amgen; Foundation Medicine
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix
Stock and Other Ownership Interests - CureMatch; IDbyDNA; Soluventis
Honoraria - AACR; Advanced Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; LEK; NeoGenomics Laboratories; NeoMed; Roche; Wiley
Consulting or Advisory Role - Actuate Therapeutics; Gaido; Loxo; Merck; NeoMed; Pfizer; Roche; Soluventis; XBiotech
Speakers' Bureau - Roche
Research Funding - Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); Merck Serono (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst)
Travel, Accommodations, Expenses - AACR; Advanced Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; LEK; NeoGenomics Laboratories; NeoMed; Roche; Wiley